Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Dabrafenib shows higher response and lower toxicity in paediatric brain cancer trial

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.10.16
Views: 2089
Rating:

Dr Mark Kieran - Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, USA

Dr Kieran talks to ecancertv at ESMO 2016 about the results of a phase I/II trial of dabrafenib therapy, which demonstrated  higher response and lower toxicity in paediatric brain tumours.

He discusses how the BRAF inhibitor has significant impact on gliomas in children, with none of the side effects seen in adult melanoma patients, and introduces upcoming doublet trials alongside a MEK inhibitor.

Read the news story for more.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation